Comparative Pharmacology
Head-to-head clinical analysis: MEPRIAM versus MILTOWN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPRIAM versus MILTOWN.
MEPRIAM vs MILTOWN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mepriam is a thiazide-like diuretic that inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride, leading to increased diuresis and vasodilation.
Miltown (meprobamate) is a carbamate derivative that acts as a central nervous system depressant. Its mechanism of action is not fully understood, but it is believed to exert its effects by modulating GABAergic neurotransmission, possibly by binding to GABA receptors and enhancing inhibitory neurotransmission. It also has sedative, anxiolytic, and muscle relaxant properties.
Adults: 500 mg IV every 24 hours.
400 mg orally 3-4 times daily; maximum 2400 mg/day.
None Documented
None Documented
The terminal elimination half-life of MEPRIAM is 12–15 hours (mean 13.5 h) in healthy adults, allowing once-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 30–40 hours, requiring dose adjustment.
10 hours (range 6-17 hours); prolonged in hepatic or renal impairment.
MEPRIAM is predominantly eliminated via renal excretion (approximately 85% as unchanged drug and metabolites) and about 15% via fecal/biliary routes. Renal clearance accounts for ~70% of total clearance.
Primarily renal, with 10-20% excreted unchanged; remainder as inactive metabolites (e.g., hydroxymeprobamate). Less than 2% fecal.
Category C
Category C
Anxiolytic
Anxiolytic